Aspirin did not provide any clinical benefits in a cohort of patients with colorectal cancer who had no history of cardiovascular disease or stroke.

Researchers, federal employees, and members of the public have voiced concerns about restrictions recently placed on federal health agencies.

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

The FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ingredients.

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

Adding pamrevlumab to chemotherapy did not improve survival in patients with previously untreated, locally advanced pancreatic cancer.

A growing body of research suggests that exposure to PFAS, commonly called "forever chemicals," may increase a person's risk ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

Neoadjuvant CRT plus sintilimab yielded a higher pCR rate than neoadjuvant chemo plus sintilimab in patients with locally advanced ESCC.

Policies that improve payer coverage, streamline authorization processes, and reduce cost-sharing burdens for medical equipment are urgently needed,” according to researchers.

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.